[Drugs for obesity. Why are obese patients diferent?].
García-Luna
P P
PP
Unidad de Nutrición Clínica, Hospitales Universitarios Virgen del Rocío, Sevilla. ppgarcia@hvr.sas.cica.es
Soto Moreno
A M
AM
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D002648:Child; D003503:Cyclobutanes / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007356:Insurance, Pharmaceutical Services; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D000077403:Orlistat; D013030:Spain / Q000453:epidemiology
D019440:Anti-Obesity Agents; D003503:Cyclobutanes; D007783:Lactones; D000077403:Orlistat; C058254:sibutramine